Combination of Pravastatin and Cyclosporin in Transplant Patients

This publication has 11 references indexed in Scilit:

• In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
  European Journal of Clinical Pharmacology, 1996
• Clinically Significant Drug Interactions with Cyclosporin
  Clinical Pharmacokinetics, 1996
• Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression.
  1995
• [Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity].
  1995
• Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary Hypercholesterolemia
  Annals of Pharmacotherapy, 1995
• Low-Dose Simvastatin Is a Well-Tolerated and Efficacious Cholesterol-Lowering Agent in Ciclosporin-Treated Kidney Transplant Recipients: Double-Blind, Randomized, Placebo-Controlled Study in 40 Patients
  Nephron, 1994
• Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients.
  1993
• Hyperlipidemia and transplantation: etiologic factors and therapy.
  1992
• Low-dose lovastatin safely lowers cholesterol after cardiac transplantation.
  1990
• Risk factors for accelerated atherosclerosis in renal transplant recipients
  The American Journal of Medicine, 1988